Furthermore, there was a smaller proportion than the general prevalence of sensitizing EGFR mutation in this cohort (34.7%) which represented physician selections of preferred non-oncogenic addicted advanced stage lung cancer for anti-angiogenic treatment. The gene discussed is EGFR; the disease is lung cancer.